These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 31227395

  • 1. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
    Singh A, Bhattacharyya N, Srivastava A, Pruett N, Ripley RT, Schrump DS, Hoang CD.
    Mol Ther; 2019 Sep 04; 27(9):1665-1680. PubMed ID: 31227395
    [Abstract] [Full Text] [Related]

  • 2. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
    Mairinger FD, Walter RF, Ting S, Vollbrecht C, Kollmeier J, Griff S, Hager T, Mairinger T, Christoph DC, Theegarten D, Schmid KW, Wohlschlaeger J.
    Future Oncol; 2014 May 04; 10(6):995-1005. PubMed ID: 24941985
    [Abstract] [Full Text] [Related]

  • 3. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
    Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G, Calabrese F, Conte PF, Ciminale V, Pasello G.
    Oncotarget; 2017 Jul 04; 8(27):44232-44241. PubMed ID: 28562336
    [Abstract] [Full Text] [Related]

  • 4. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G, Urso L, Mencoboni M, Grosso F, Ceresoli GL, Lunardi F, Vuljan SE, Bertorelle R, Sacchetto V, Ciminale V, Rea F, Favaretto A, Conte P, Calabrese F.
    Oncotarget; 2015 Dec 08; 6(39):42053-66. PubMed ID: 26544728
    [Abstract] [Full Text] [Related]

  • 5. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C, Liu J, Tan C, Yue X, Zhao Y, Peng J, Wang X, Laddha SV, Chan CS, Zheng S, Hu W, Feng Z.
    Oncotarget; 2016 Feb 23; 7(8):8783-96. PubMed ID: 26840028
    [Abstract] [Full Text] [Related]

  • 6. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJ, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G.
    J Thorac Oncol; 2013 Oct 23; 8(10):1317-28. PubMed ID: 24457242
    [Abstract] [Full Text] [Related]

  • 7. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
    Fortunato O, Boeri M, Moro M, Verri C, Mensah M, Conte D, Caleca L, Roz L, Pastorino U, Sozzi G.
    Cell Death Dis; 2014 Dec 11; 5(12):e1564. PubMed ID: 25501825
    [Abstract] [Full Text] [Related]

  • 8. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G.
    Mol Cancer; 2016 Jun 01; 15(1):44. PubMed ID: 27245839
    [Abstract] [Full Text] [Related]

  • 9. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
    Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N.
    Ann Oncol; 2013 Dec 01; 24(12):3128-35. PubMed ID: 24148817
    [Abstract] [Full Text] [Related]

  • 10. miR-1 induces growth arrest and apoptosis in malignant mesothelioma.
    Xu Y, Zheng M, Merritt RE, Shrager JB, Wakelee HA, Kratzke RA, Hoang CD.
    Chest; 2013 Nov 01; 144(5):1632-1643. PubMed ID: 23828229
    [Abstract] [Full Text] [Related]

  • 11. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M, Atay SM, Shukla V, Hong Y, Upham T, Ripley RT, Hong JA, Zhang M, Reardon E, Fetsch P, Miettinen M, Li X, Peer CJ, Sissung T, Figg WD, De Rienzo A, Bueno R, Schrump DS.
    Clin Cancer Res; 2016 Mar 01; 22(5):1197-210. PubMed ID: 26459178
    [Abstract] [Full Text] [Related]

  • 12. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
    Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJ, Vallely MP, McCaughan BC, Cooper W, Klebe S, Lin RC, Brahmbhatt H, MacDiarmid J, van Zandwijk N, Reid G.
    Oncotarget; 2015 Sep 15; 6(27):23480-95. PubMed ID: 26125439
    [Abstract] [Full Text] [Related]

  • 13. miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation.
    Wang M, Gu H, Qian H, Zhu W, Zhao C, Zhang X, Tao Y, Zhang L, Xu W.
    Eur J Cancer; 2013 May 15; 49(8):2010-21. PubMed ID: 23333058
    [Abstract] [Full Text] [Related]

  • 14. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.
    J Thorac Oncol; 2017 Sep 15; 12(9):1421-1433. PubMed ID: 28629895
    [Abstract] [Full Text] [Related]

  • 15. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L, Xu J, Zhao F, Dai X, Tao J, Pan J, Shi A, Shen Z, Su C, Zhang Y.
    Eur J Pharmacol; 2021 May 15; 899():174054. PubMed ID: 33771522
    [Abstract] [Full Text] [Related]

  • 16. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
    Tian K, Bakker E, Hussain M, Guazzelli A, Alhebshi H, Meysami P, Demonacos C, Schwartz JM, Mutti L, Krstic-Demonacos M.
    J Transl Med; 2018 Oct 13; 16(1):282. PubMed ID: 30316293
    [Abstract] [Full Text] [Related]

  • 17. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G.
    J Thorac Oncol; 2018 Feb 13; 13(2):258-272. PubMed ID: 29113949
    [Abstract] [Full Text] [Related]

  • 18. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L, Tounsi A, Berenguer-Daizé C, Dussault N, Delfino C, Benyahia Z, Cayol M, Mabrouk K, Garcia S, Martin PM, Barlesi F, Ouafik L.
    J Thorac Oncol; 2016 Jan 13; 11(1):94-107. PubMed ID: 26762744
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld J, Iorio F, Kolluri K, Garnett M, Berns A, Baas P, McDermott U, Neefjes J, Alifrangis C.
    Clin Cancer Res; 2018 Jan 01; 24(1):84-94. PubMed ID: 29061644
    [Abstract] [Full Text] [Related]

  • 20. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K, Seike M, Takeuchi S, Soeno C, Miyanaga A, Noro R, Minegishi Y, Kubota K, Gemma A.
    Oncol Rep; 2014 Dec 01; 32(6):2365-72. PubMed ID: 25231602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.